National sponsor of the Motherisk Program
Our Helplines
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Current Studies at Motherisk
-
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
-
Pregnancy in Women with Multiple Sclerosis
-
Environmental Exposures and Children's Health
-
Alcohol Use during Pregnancy
-
Control of Hypertension in Pregnancy Study
-
Folic Acid Before and During Pregnancy
-
Lamisil in Pregnancy
-
Meridia in Pregnancy
-
Autoimmune Diseases in Pregnancy Project
Conditions in Pregnancy: Use of ACE inhibitors
Motherisk research in 2011 found that the use of ACE inhibitors to treat hypertension during the first trimester of pregnancy may be associated with a higher risk of miscarriage.
Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are known to cause fetal renal damage in pregnancy. Due to conflicting reports in the literature, their safety after first trimester exposure has been debated. Our aim was to determine whether the use of ACE inhibitors or ARBs in the first trimester of pregnancy is associated with an increased risk for major malformations or other adverse outcomes. Motherisk's study results suggest that ACE inhibitors/ARBs are not major human teratogens; however, they may be associated with an increased risk for miscarriage.
Read the research:
The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Obstet Gynecol Int. 2012;2012:658310. Epub 2011 Dec 13. [see article ]
Read more about ACE inhibitors:
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol. 2011 Aug;31(6):465-72.
[see article ]
![[Valid RSS]](/images/rssValid.png "Validate my RSS feed")